E
BEAM icon

Ergoteles’s Beam Therapeutics BEAM Stock Holding History

Ergoteles’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-44,574
Closed -$3.55M – 1226
2021
Q4 		$3.55M Buy
+44,574
New +$3.82M 0.14% 156
2021
Q2 		– Sell
-116,855
Closed -$9.35M – 1493
2021
Q1 		$9.35M Buy
+116,855
New +$11.1M 0.29% 87

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's BEAM Position: Q1 2022 in Review

Ergoteles sold out of Beam Therapeutics (BEAM) in Q1 2022, closing a stake of 44,574 shares — an estimated $3.55M sold.

Ergoteles first reported a position in BEAM in Q1 2021 and held it in 2 quarters. The position peaked at $9.35M in Q1 2021. 240 funds tracked by Wall St. Rank hold BEAM as of Q1 2022.

  • Ergoteles reported no remaining Beam Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Ergoteles sold 44,574 Beam Therapeutics shares in Q1 2022, an estimated $3.55M.
  • Ergoteles first reported a position in Beam Therapeutics in Q1 2021 and held it in 2 quarters.
  • Ergoteles's Beam Therapeutics position peaked at $9.35M in Q1 2021.
  • 240 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.